AgenusNASDAQ: AGEN

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, is pleased to announce the appointment of Dr. Jennifer Buell to its Board of Directors, on June 11, 2024, effective immediately. Dr. Buell will maintain her active and ongoing role as the President and CEO of MiNK Therapeutics, in addition to her responsibilities as Chairman of the Executive Council at Agenus. Her continued leadership at MiNK ensu.

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus has published results from a groundbreaking clinical trial in Nature Medicine, revealing the potential of a novel immunotherapy combination for treating microsatellite stable metastatic colorectal cancer (MSS mCRC), a cancer type historically resistant to immunotherapy. This pioneering research, led by an international team of oncologists, focuses on the efficacy and safety of botensilimab (BOT), an Fc-enhanced anti-CTLA-4 antibody, in combination with.

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June 11, 2024, and will be conducted in a virtual format only. Registration for attendees will start at 10:15 a.m. ET. To participate in the Annual Shareholders Meeting, shareholders should visit www.virtualshareholdermeeting.com/AGEN2024 and enter.

Human life expectancy has doubled since the 1900s, mostly attributed to advancements in lifestyle, living standards and medicine. Thanks to biotech companies that produce transformative drugs and treatments, we now have the collective ability to combat diseases that used to bring entire nations down.

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the Compensation Committee of Agenus' Board of Directors granted inducement awards to Eric Olson, in connection with his appointment as Head of Regulatory. The Compensation Committee approved the awards pursuant to Agenus' 2015 Inducement Equity Plan and in accordance with Nasdaq Listing Rule 5635(c)(4). The aw.

Small- and mid-cap stocks are known to be highly sensitive to interest rates. With the Federal Reserve expected to start cutting rates no later than 2025, these equities may be on the verge of a turnaround.

Agenus Inc. will hold a Type B End-of-Phase 2 meeting with the FDA in July to discuss the BOT/BAL combination therapy studies for patients with relapsed/refractory metastatic colorectal cancer.

Agenus, a small immunotherapy company, saw a 40% increase in its stock price last Friday, as investors seem to be driving up the stock in anticipation of first-quarter earnings on May 7.

Shares of Agenus are way down this year, but the cancer drug developer still has some interesting assets. An experimental cancer therapy that just started phase 2 trials could generate more than $1 billion in milestone payments from Bristol Myers Squibb.